• for investors
  • for entrepreneurs
  • companies
  • news
  • about us
HAYA Therapeutics – A new addition to LifeLink’s portfolio

HAYA Therapeutics – A new addition to LifeLink’s portfolio

by Francisca Peixoto | May 8, 2025 | Uncategorized

We are excited to announce another exciting addition to LifeLink’s portfolio, HAYA Therapeutics. We’re very proud to have joined the $65 million Series A financing round, led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli...
AIRNA Raises Oversubscribed $155 Million Series B Financing

AIRNA Raises Oversubscribed $155 Million Series B Financing

by Francisca Peixoto | Apr 1, 2025 | Uncategorized

Our portfolio company, AIRNA, has secured an oversubscribed $155 million Series B financing round to advance its lead RNA-editing therapeutic, AIR-001, into Phase 1/2 clinical trials for alpha-1 antitrypsin deficiency (AATD). AATD is a genetic condition caused by...
Accure Therapeutics Announces Positive Phase 2 trial Results

Accure Therapeutics Announces Positive Phase 2 trial Results

by Francisca Peixoto | Feb 5, 2025 | Uncategorized

Recently, our portfolio company Accure Therapeutics announced the successful results of the ACUITY phase 2 trial in collaboration with Oculis. Accure Therapeutics, a pioneering translational neuroscience R&D company, has made significant strides in the field of...
Arda Therapeutics – A new addition to LifeLink’s portfolio

Arda Therapeutics – A new addition to LifeLink’s portfolio

by Francisca Peixoto | Oct 8, 2024 | Uncategorized

We are excited to announce another exciting addition to LifeLink’s portfolio. Arda Therapeutics $43M Series A was led by Andreessen Horowitz (a16z) Bio with participation from Eli Lilly and Company Ventures, GV (Google Ventures), Two Sigma Ventures, RV Invest,...
Spiral Therapeutics Announces Successful Completion of  Clinical Trial for Meniere’s Disease

Spiral Therapeutics Announces Successful Completion of Clinical Trial for Meniere’s Disease

by Francisca Peixoto | Oct 1, 2024 | Uncategorized

Our portfolio company Spiral Therapeutics just announced successful completion of the SPT-2101 phase 1b/2a clinical trial for Meniere’s disease, with promising results. Spiral Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing...
« Older Entries

contact us

Barcelona Spain

  • Follow
  • Follow

navigate

  • for investors
  • for entrepreneurs
  • companies
  • news
  • about us

legal conditions

  • Legal notice
  • Cookies policy
  • Privacy policy
  • Credits
  • home
  • for investors
  • for entrepreneurs
  • companies
  • news
  • about us